Biotech Values

[DewDiligence]

PFE—According to today's 1Q13 CC, the $0.06 reduction in 2013 non-GAAP EPS guidance (to $2.14-2.24 from the old range of $2.20-2.30) was due solely to two items: i) currency (especially the weakening of the yen relative to the US dollar); and ii) the timing of the ZTS IPO.